Acumen Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Acumen Pharmaceuticals şirketinin toplam hissedar öz sermayesi $243.9M ve toplam borcu $29.4M olup, bu da borç-öz sermaye oranını 12% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla $288.9M ve $45.0M dir.

Anahtar bilgiler

12.0%

Borç/özkaynak oranı

US$29.38m

Borç

Faiz karşılama oranı	n/a
Nakit	US$260.47m
Eşitlik	US$243.95m
Toplam yükümlülükler	US$44.97m
Toplam varlıklar	US$288.91m

Son finansal sağlık güncellemeleri

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Aug 05

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Apr 21

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10

Recent updates

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Sep 21

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Feb 01

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 16

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Sep 28

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Jun 30

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

May 10

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Jan 07

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Oct 01

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ABOS 'nin kısa vadeli varlıkları ( $266.9M ) kısa vadeli yükümlülüklerini ( $15.4M ) aşıyor.

Uzun Vadeli Yükümlülükler: ABOS şirketinin kısa vadeli varlıkları ( $266.9M ) uzun vadeli yükümlülüklerini ( $29.6M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ABOS şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ABOS şirketinin borç/öz sermaye oranının son 5 yılda azalıp azalmadığını belirlemek için yeterli veri yok.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ABOS şirketinin mevcut serbest nakit akışına göre 3 yıldan fazla bir süre için yeterli nakit pistine sahip olduğu belirtiliyor.

Tahmini Nakit Akışı: ABOS serbest nakit akışı her yıl % 43.4 2.2 yıl yetecek nakit akışına sahip olacaktır.

Acumen Pharmaceuticals Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

Recent updates

Acumen Pharmaceuticals, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Does Acumen Pharmaceuticals (NASDAQ:ABOS) Have A Healthy Balance Sheet?

Acumen Pharmaceuticals, Inc. Presents Patient Experience and Biomarker Data from Phase 1 INTERCEPT-AD Study at the Alzheimer’s Association International Conference (AAIC) 2024

Acumen Pharmaceuticals: Healthy Cash Runway And Market Potential In Alzheimer's

Acumen Pharmaceuticals, Inc. to Report Q1, 2024 Results on May 14, 2024

Acumen Pharmaceuticals, Inc., Annual General Meeting, Jun 04, 2024

Is Acumen Pharmaceuticals (NASDAQ:ABOS) Weighed On By Its Debt Load?

Acumen Pharmaceuticals, Inc. to Report Q4, 2023 Results on Mar 26, 2024

Acumen Pharmaceuticals, Inc. Presents Sabirnetug (ACU193) Fluid Biomarker and Target Engagement Analyses from Phase 1 INTERCEPT-AD Study in Early Alzheimer's At the AD/PD 2024 Annual Meeting

Acumen Pharmaceuticals, Inc. Appoints James Doherty as Its President and Chief Development Officer

Price target decreased by 8.4% to US$14.00

CEO, President & Director notifies of intention to sell stock

Price target increased by 8.6% to US$16.60

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. announced that it expects to receive $50 million in funding

Acumen Pharmaceuticals, Inc. to Report Q3, 2023 Results on Nov 13, 2023

Acumen Pharmaceuticals, Inc. Presents Late-Breaker Phase 1 Updates Exploring Novel Target Engagement, Dosing Regimen and Safety Findings for ACU193 in Early Alzheimer's Disease at the 16th Annual Clinical Trials on Alzheimer's Disease

Acumen Pharmaceuticals, Inc. to Present Deeper Insights from First-In-Human Phase 1 Study of ACU193 for Early Alzheimer’s During Symposium At the 16Th Annual Clinical Trials on Alzheimer’s Disease (CTAD)

Companies Like Acumen Pharmaceuticals (NASDAQ:ABOS) Are In A Position To Invest In Growth

Independent Director notifies of intention to sell stock

Acumen Pharmaceuticals, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New minor risk - Shareholder dilution

Acumen Pharmaceuticals, Inc. Presents Positive Topline Results from First-in-Human Phase 1 Study of ACU193 for Early Alzheimer’s Disease at the Alzheimer’s Association International Conference (AAIC) 2023

Price target decreased by 8.0% to US$14.57

Acumen Pharmaceuticals Completes Enrollment in Phase 1 Trial of Acu193, First Monoclonal Antibody Developed to Selectively Target Toxic A<Beta> Oligomers in Patients with Early Alzheimer's Disease

Acumen Pharmaceuticals Provides Updates with Respect to INTERCEPT-AD

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Acumen Pharmaceuticals Appoints Derrell Porter, M.D., to Its Board of Directors

Price target increased to US$17.20

Key Executive exercised options to buy US$273k worth of stock.

Acumen Pharmaceuticals, Inc. to Report Q3, 2022 Results on Nov 14, 2022

Acumen Pharmaceuticals, Inc. Publishes Phase 1 Trial Design and Clinical Development Plan for ACU193

Acumen Pharmaceuticals, Inc. Acu193, an Anti-Amyloid Beta Oligomer Antibody, Granted Fda Fast Track Designation for Alzheimer's Disease

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Price target increased to US$16.00

Acumen Pharma at 11-month high on rivals’ Alzheimer’s data

Acumen Pharmaceuticals, Inc. Announces Resignation of Dr. Jeffrey Sevigny to Its Board of Directors

Acumen Pharmaceuticals, Inc. to Report Q2, 2022 Results on Aug 15, 2022

Acumen Pharmaceuticals initiated at buy at H.C. Wainwright on Alzheimer's candidate

Acumen Pharmaceuticals, Inc.(NasdaqGS:ABOS) dropped from Russell 2500 Value Index

Acumen Pharmaceuticals, Inc. to Report Q1, 2022 Results on May 16, 2022

We Think Acumen Pharmaceuticals (NASDAQ:ABOS) Can Afford To Drive Business Growth

Full year 2021 earnings released

Acumen Pharmaceuticals, Inc. Announces Management Changes

We're Not Very Worried About Acumen Pharmaceuticals' (NASDAQ:ABOS) Cash Burn Rate

Third quarter 2021 earnings released: US$0.10 loss per share

Acumen Pharmaceuticals (NASDAQ:ABOS) Is In A Good Position To Deliver On Growth Plans

Acumen Pharmaceuticals, Inc. has completed an IPO in the amount of $159.999984 million.

Finansal Durum Analizi

Borç-Özkaynak Tarihçesi ve Analizi

Bilanço

Nakit Pist Analizi

Sağlıklı şirketleri keşfedin